Filtered By:
Condition: Blindness
Drug: Fortamet

This page shows you your search results in order of date.

Order by Relevance | Date

Total 4 results found since Jan 2013.

Impact of Active Antihyperglycemic Components as herbal therapy for Preventive Health Care Management of Diabetes.
Abstract Diabetes is a metabolic hyperglycemic condition that progressively develops, effect small and large sensory fibers in affected population. It has various complications as hypertension, coronary artery disease, stroke, blindness, kidney disease as well as peripheral neuropathy. Sulfonylureas, thiazolidinediones, metformin, biguanidine, acarbose and insulin are commonly used drugs by diabetic patients, but these all have certain side effects. Even metformin, that is known as the miracle drug for diabetes has been found to be associated with side effects, as during treatment it involves complications with ey...
Source: Current Molecular Medicine - February 19, 2019 Category: Molecular Biology Authors: Kashyap H, Gupta S, Bist R Tags: Curr Mol Med Source Type: research

Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
CONCLUSIONS: AGI may prevent or delay the development of T2DM in people with IGT. There is no firm evidence that AGI have a beneficial effect on cardiovascular mortality or cardiovascular events. PMID: 30592787 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - December 28, 2018 Category: General Medicine Authors: Moelands SV, Lucassen PL, Akkermans RP, De Grauw WJ, Van de Laar FA Tags: Cochrane Database Syst Rev Source Type: research

EBN resources page
Drug and Therapeutics Bulletin (DTB) April, May, June 2013 issues http://dtb.bmj.com HbA1c targets in type 2 diabetes: guidelines and evidence Aims of treatment for type-2 diabetes include minimising long-term complications (eg, cardiovascular disease, blindness, chronic kidney disease, premature mortality) and avoiding the unwanted effects of treatment (eg, severe hypoglycaemia, weight gain). Publication of the UK Prospective Diabetes Study (UKPDS) 33 in 1998 suggested that ‘intensive blood glucose control’ to lower the glycated haemoglobin (HbA1c) in people with type 2 diabetes reduced microvascular disease b...
Source: Evidence-Based Nursing - December 10, 2013 Category: Nursing Authors: Noble, E. b. H. Tags: Diarrhoea, Immunology (including allergy), Drugs: infectious diseases, Urinary tract infections, Stroke, Hypertension, Obesity (nutrition), Cervical cancer, Pregnancy, Reproductive medicine, Colon cancer, Gynecological cancer, Ophthalmology, Complementary Source Type: research

Diabetes drugs may be linked to pancreatic cancer
Conclusion This article presents important concerns that glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors could potentially increase the risk of inflammation and cancerous changes in the pancreas. The agencies that regulate medicines in Europe and the USA are aware of these issues, and told the BMJ that their analyses show increased reporting of pancreatic cancer among people taking these types of drugs. However, the agencies note that it has not been established whether these drugs directly cause the adverse effects seen in the pancreas. Both agencies are reviewing emerging eviden...
Source: NHS News Feed - June 10, 2013 Category: Consumer Health News Tags: Medication Diabetes QA articles Source Type: news